Advances in antimicrobial orthopaedic devices and FDA regulatory challenges

Area of Science:

• Orthopaedic surgery
• Biomaterials science
• Infectious diseases

Background:

• Implant-associated infections, driven by biofilms from antibiotic-resistant organisms, are a primary cause of orthopaedic implant failure.
• Current strategies focus on inhibiting bacterial growth or adherence, but clinical translation remains limited.
• A significant barrier to clinical adoption is the disconnect between research and regulatory bodies.

Purpose of the Study:

• To review current strategies for minimizing orthopaedic implant-associated infections.
• To discuss regulatory perspectives and challenges from agencies like the Food and Drug Administration (FDA).
• To highlight emerging technologies and future directions in combating implant infections.

Main Methods:

• Literature review of recent strategies for preventing orthopaedic implant infections.
• Analysis of Food and Drug Administration (FDA) regulatory viewpoints and hurdles.
• Identification and discussion of novel and emerging technologies in the field.

Main Results:

• Several strategies exist to combat implant infections, but none are fully established clinically.
• Regulatory pathways and challenges present significant obstacles to translating new technologies.
• Emerging technologies aim for long-term or permanent antibacterial properties without antimicrobial compounds.

Conclusions:

• Developing effective, long-term antibacterial orthopaedic implants requires addressing both technical and regulatory challenges.
• Future research should focus on strategies that avoid antimicrobial resistance and preserve osseointegration.
• Bridging the gap between researchers and regulatory agencies is crucial for clinical translation.